Celgene gets option to acquire VentiRx through new TLR8 agonist development deal
- Specialty Pharmaceuticals
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.